Join CancerNetwork’s Prostate Cancer Tweet Chat

Article

CancerNetwork® will be hosting a tweet chat that will feature mock tumor board on prostate cancer this Friday, October 30th, at 12 PM EST.

Join CancerNetwork® on Twitter this Friday, October 30th, at 12 PM EST for a tweet chat on prostate cancer.

This mock tumor board will discuss real patient cases and present various treatment options for review, with guest commentary on each case offered from experts in the field.

Led by Judd W. Moul, MD, FACS, a urologic oncologist at Duke Cancer Center and Duke Urology Clinic, the chat will feature guest commentary from Daniel Spratt, MD, chief of the Genitourinary Radiotherapy Program, associate chair of Clinical Research, and the Laurie Snow Endowed Research Professor at the Rogel Cancer Center of the University of Michigan, Alicia K. Morgans, MD, MPH, associate professor of Medicine at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine, and Stacy Loeb, MD, MSc, PhD (hon.), professor of Urology and Population Health at NYU Langone Health and the Manhattan Veterans Affairs.

To participate in the chat, just follow the directions below.

prostate cancer tweet chat how to

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content